<?xml version="1.0" encoding="UTF-8"?>
<OAI-PMH xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2024-05-03T01:29:54Z</responseDate>
  <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:9999287" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request>
  <GetRecord>
    <record>
      <header>
        <identifier>oai:pubmedcentral.nih.gov:9999287</identifier>
        <datestamp>2023-03-11</datestamp>
        <setSpec>jamasd</setSpec>
        <setSpec>pmc-open</setSpec>
      </header>
      <metadata>
        <article xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.3/ https://jats.nlm.nih.gov/archiving/1.3/xsd/JATS-archivearticle1-3.xsd" dtd-version="1.3" xml:lang="en" article-type="research-article">
          <processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
            <restricted-by>pmc</restricted-by>
          </processing-meta>
          <front>
            <journal-meta>
              <journal-id journal-id-type="nlm-ta">JAMA Oncol</journal-id>
              <journal-id journal-id-type="iso-abbrev">JAMA Oncol</journal-id>
              <journal-title-group>
                <journal-title>JAMA Oncology</journal-title>
              </journal-title-group>
              <issn pub-type="ppub">2374-2437</issn>
              <issn pub-type="epub">2374-2445</issn>
              <publisher>
                <publisher-name>American Medical Association</publisher-name>
              </publisher>
            </journal-meta>
            <article-meta>
              <article-id pub-id-type="accession">PMC9999287</article-id>
              <article-id pub-id-type="pmcid">PMC9999287</article-id>
              <article-id pub-id-type="pmc-uid">9999287</article-id>
              <article-id pub-id-type="pmid">36892847</article-id>
              <article-id pub-id-type="pmid">36892847</article-id>
              <article-id pub-id-type="doi">10.1001/jamaoncol.2022.7949</article-id>
              <article-id pub-id-type="publisher-id">coi220102</article-id>
              <article-categories>
                <subj-group subj-group-type="category" specific-use="electronic">
                  <subject>Research</subject>
                </subj-group>
                <subj-group subj-group-type="domain" specific-use="print">
                  <subject>Research</subject>
                </subj-group>
                <subj-group subj-group-type="heading">
                  <subject>Original Investigation</subject>
                </subj-group>
                <subj-group subj-group-type="online-first">
                  <subject>Online First</subject>
                </subj-group>
                <subj-group subj-group-type="allowCommenting">
                  <subject>Comments</subject>
                </subj-group>
              </article-categories>
              <title-group>
                <article-title>Evaluation of Alisertib Alone or Combined With Fulvestrant in Patients With Endocrine-Resistant Advanced Breast Cancer</article-title>
                <subtitle>The Phase 2 TBCRC041 Randomized Clinical Trial</subtitle>
                <alt-title alt-title-type="headline">Evaluation of Alisertib Alone or Combined With Fulvestrant in Patients With Endocrine-Resistant Advanced Breast Cancer</alt-title>
                <alt-title alt-title-type="running-head">Evaluation of Alisertib Alone or Combined With Fulvestrant in Patients With Endocrine-Resistant Advanced Breast Cancer</alt-title>
              </title-group>
              <contrib-group>
                <contrib contrib-type="author" corresp="yes">
                  <name>
                    <surname>Haddad</surname>
                    <given-names>Tufia C.</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <xref rid="coi220102aff1" ref-type="aff">
                    <sup>1</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Suman</surname>
                    <given-names>Vera J.</given-names>
                  </name>
                  <degrees>PhD</degrees>
                  <xref rid="coi220102aff2" ref-type="aff">
                    <sup>2</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>D’Assoro</surname>
                    <given-names>Antonino B.</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <degrees>PhD</degrees>
                  <xref rid="coi220102aff1" ref-type="aff">
                    <sup>1</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Carter</surname>
                    <given-names>Jodi M.</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <degrees>PhD</degrees>
                  <xref rid="coi220102aff3" ref-type="aff">
                    <sup>3</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Giridhar</surname>
                    <given-names>Karthik V.</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <xref rid="coi220102aff1" ref-type="aff">
                    <sup>1</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>McMenomy</surname>
                    <given-names>Brendan P.</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <xref rid="coi220102aff4" ref-type="aff">
                    <sup>4</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Santo</surname>
                    <given-names>Katelyn</given-names>
                  </name>
                  <degrees>BS</degrees>
                  <xref rid="coi220102aff2" ref-type="aff">
                    <sup>2</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Mayer</surname>
                    <given-names>Erica L.</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <degrees>MPH</degrees>
                  <xref rid="coi220102aff5" ref-type="aff">
                    <sup>5</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Karuturi</surname>
                    <given-names>Meghan S.</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <xref rid="coi220102aff6" ref-type="aff">
                    <sup>6</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Morikawa</surname>
                    <given-names>Aki</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <degrees>PhD</degrees>
                  <xref rid="coi220102aff7" ref-type="aff">
                    <sup>7</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Marcom</surname>
                    <given-names>P. Kelly</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <xref rid="coi220102aff8" ref-type="aff">
                    <sup>8</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Isaacs</surname>
                    <given-names>Claudine J.</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <xref rid="coi220102aff9" ref-type="aff">
                    <sup>9</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Oh</surname>
                    <given-names>Sun Young</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <xref rid="coi220102aff10" ref-type="aff">
                    <sup>10</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Clark</surname>
                    <given-names>Amy S.</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <xref rid="coi220102aff11" ref-type="aff">
                    <sup>11</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Mayer</surname>
                    <given-names>Ingrid A.</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <xref rid="coi220102aff12" ref-type="aff">
                    <sup>12</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Keyomarsi</surname>
                    <given-names>Khandan</given-names>
                  </name>
                  <degrees>PhD</degrees>
                  <xref rid="coi220102aff13" ref-type="aff">
                    <sup>13</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Hobday</surname>
                    <given-names>Timothy J.</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <xref rid="coi220102aff1" ref-type="aff">
                    <sup>1</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Peethambaram</surname>
                    <given-names>Prema P.</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <xref rid="coi220102aff1" ref-type="aff">
                    <sup>1</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>O’Sullivan</surname>
                    <given-names>Ciara C.</given-names>
                  </name>
                  <degrees>MB</degrees>
                  <degrees>BCh</degrees>
                  <xref rid="coi220102aff1" ref-type="aff">
                    <sup>1</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Leon-Ferre</surname>
                    <given-names>Roberto A.</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <xref rid="coi220102aff1" ref-type="aff">
                    <sup>1</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Liu</surname>
                    <given-names>Minetta C.</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <xref rid="coi220102aff1" ref-type="aff">
                    <sup>1</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Ingle</surname>
                    <given-names>James N.</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <xref rid="coi220102aff1" ref-type="aff">
                    <sup>1</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Goetz</surname>
                    <given-names>Matthew P.</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <xref rid="coi220102aff1" ref-type="aff">
                    <sup>1</sup>
                  </xref>
                </contrib>
              </contrib-group>
              <aff id="coi220102aff1"><label>1</label>Department of Oncology, Mayo Clinic, Rochester, Minnesota</aff>
              <aff id="coi220102aff2"><label>2</label>Department of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota</aff>
              <aff id="coi220102aff3"><label>3</label>Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota</aff>
              <aff id="coi220102aff4"><label>4</label>Department of Radiology, Mayo Clinic, Rochester, Minnesota</aff>
              <aff id="coi220102aff5"><label>5</label>Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts</aff>
              <aff id="coi220102aff6"><label>6</label>Department of Breast Medical Oncology, MD Anderson Cancer Center, Houston, Texas</aff>
              <aff id="coi220102aff7"><label>7</label>Department of Medicine, University of Michigan, Ann Arbor</aff>
              <aff id="coi220102aff8"><label>8</label>Department of Medicine, Duke University Cancer Institute, Durham, North Carolina</aff>
              <aff id="coi220102aff9"><label>9</label>Department of Medicine, Georgetown University, Washington, DC</aff>
              <aff id="coi220102aff10"><label>10</label>Department of Medical Oncology, Albert Einstein College of Medicine/Montefiore Medical Center, Bronx, New York</aff>
              <aff id="coi220102aff11"><label>11</label>Department of Medicine, University of Pennsylvania, Philadelphia</aff>
              <aff id="coi220102aff12"><label>12</label>Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee</aff>
              <aff id="coi220102aff13"><label>13</label>Department of Experimental Radiation Oncology, MD Anderson Cancer Center, Houston, Texas</aff>
              <author-notes>
                <title>Article Information</title>
                <p><bold>Accepted for Publication:</bold> November 23, 2022.</p>
                <p content-type="published-online"><bold>Published Online:</bold> March 9, 2023. <?xpp bx;1?>doi:<uri content-type="doi">10.1001/jamaoncol.2022.7949</uri></p>
                <corresp id="coi220102cor1"><bold>Corresponding Author:</bold> Tufia Haddad, MD, Department of Oncology, Mayo Clinic, 200 First St SW, Rochester, MN 55905 (<email xlink:href="haddad.tufia@mayo.edu">haddad.tufia@mayo.edu</email>).</corresp>
                <p content-type="open-access-note"><bold>Open Access:</bold> This is an open access article distributed under the terms of the <ext-link xlink:href="https://jamanetwork.com/pages/cc-by-license-permissions" ext-link-type="uri">CC-BY License</ext-link>. © 2023 Haddad TC et al. <italic>JAMA Oncology</italic>.</p>
                <p content-type="author-contributions"><bold>Author Contributions:</bold> Drs Haddad and Suman had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.</p>
                <p><italic>Concept and design:</italic> Haddad, Suman, D’Assoro, I. Mayer, Keyomarsi, Liu, Ingle, Goetz.</p>
                <p><italic>Acquisition, analysis, or interpretation of data:</italic> Haddad, Suman, Carter, Giridhar, McMenomy, Santo, E. Mayer, Karuturi Sri, Morikawa, Marcom, Isaacs, Oh, Clark, I. Mayer, Hobday, Peethambaram, O’Sullivan, Leon-Ferre, Liu, Ingle, Goetz.</p>
                <p><italic>Drafting of the manuscript:</italic> Haddad, Suman, D’Assoro, Santo, Clark, Peethambaram, O’Sullivan, Goetz.</p>
                <p><italic>Critical revision of the manuscript for important intellectual content:</italic> Haddad, Suman, Carter, Giridhar, McMenomy, E. Mayer, Karuturi Sri, Morikawa, Marcom, Isaacs, Oh, Clark, I. Mayer, Keyomarsi, Hobday, Leon-Ferre, Liu, Ingle, Goetz.</p>
                <p><italic>Statistical analysis:</italic> Suman, Santo.</p>
                <p><italic>Obtained funding:</italic> Haddad.</p>
                <p><italic>Administrative, technical, or material support:</italic> D’Assoro, McMenomy, Morikawa, Isaacs, Clark, Keyomarsi, O’Sullivan, Leon-Ferre, Liu, Goetz.</p>
                <p><italic>Supervision:</italic> Haddad, Peethambaram, O’Sullivan, Goetz.</p>
                <p><italic>Other:</italic> Carter, Clark.</p>
                <p content-type="COI-statement"><bold>Conflict of Interest Disclosures:</bold> Dr Haddad reported grant funding from Takeda Oncology for the conduct of the clinical trial that was associated with this manuscript but she did not receive any personal funding, as all dollars went to the Mayo Clinic. Dr E. Mayer reported consulting fees from Lilly, Novartis, AstraZeneca, and Gilead outside the submitted work. Dr Karuturi Sri reported personal fees from Lilly and Gilead during the conduct of the study. Dr Morikawa reported research support from Takeda and Eisai during the conduct of the study as well as personal fees from Seagen, Lilly, and Eisai, reviewer fees from Taiho, grants from Pfizer, nonfinancial support from Tempus, and research support from MTEM, Dantari, Suzhou Zanrong Pharma limited (formerly Zion), Merck, Roche, Puma, and Novartis outside the submitted work. Dr Isaacs reported personal fees from Genentech, Puma Seattle Genetics, AstraZeneca, Novartis, Pfizer, Sanofi, Gilead, ION, Wolters Kluwer, McGraw Hill, and SideOut Foundation as well as grants from GSK and Pfizer outside the submitted work. Dr Clark reported grants from Novartis and Lilly, steering committee service for Novartis Scientific, and honoraria from Siemens during the conduct of the study. Dr I. Mayer reported personal fees from AstraZeneca, Genentech, Lilly, Puma, Novartis, GSK, Polyphor, Macrogenics, SeaGen, AbbVie, Immunomedics, Cyclacel, Blueprint, and Pfizer as well as employment with AstraZeneca outside the submitted work. Dr Keyomarsi reported research funding outside the submitted work from Repare Therapeutics (institutional), Apeiron Biologics (institutional), Blueprint Medicines (institutional), Schrodinger Inc (institutional), the National Institutes of Health (NIH), and National Cancer Institute R01 grants CA255960 and CA223772 and CPRIT multiinvestigator grant RP180712. Dr O’Sullivan reported research support from Lilly, Seagen, Minnemarita Therapeutics, Biovica, nference, ACCRU, Bavarian Nordic, Sermonix Pharmaceuticals, and AstraZeneca. Dr Leon-Ferre reported personal fees from Gilead Sciences, Lyell Immunopharma, and AstraZeneca outside the submitted work. Dr Liu reported research support from Eisai, Exact Sciences, Genentech, Genomic Health, GRAIL, Menarini Silicon Biosystems, Merck, Novartis, Seattle Genetics, and Tesaro; employment with Natera after the submitted work was completed; and board service for AstraZeneca, Celgene, Roche/Genentech, Genomic Health, GRAIL, Ionis, Merck, Pfizer, Seattle Genetics, and Syndax outside the submitted work. Dr Ingle reported grants from the Translational Breast Cancer Research Consortium and Prospect Creek Foundation during the conduct of the study. Dr Goetz reported grants from Takeda during the conduct of the study as well as personal fees from Genomic Health, AstraZeneca, Biovica, Eli Lilly, Novartis, Context Pharm, Eagle Pharm, ARC Therapeutics, Blueprint, Biotheranostics, Sanofi Genzyme, Research to Practice, Clinical Education Alliance, Medscape, MJH Life Sciences, and Total Health and grants from AstraZeneca, Eli Lilly, and Pfizer outside the submitted work. No other disclosures were reported.</p>
                <p content-type="funding-statement"><bold>Funding/Support:</bold> This study was supported by Takeda Oncology, TBCRC foundational partner support from the Breast Cancer Research Foundation and Susan G. Komen, NIH grants K12 CA90628 (Dr Haddad) and R01 CA214893 (Drs Haddad and D’Assoro), Prospect Creek Foundation (Drs Haddad and D’Assoro), American Association for Cancer Research/American Society of Clinical Oncology Vail Workshop NIH grant R25CA068647 (Dr Haddad).</p>
                <p><bold>Role of the Funder/Sponsor:</bold> The funding entities had no role in the design and conduct of the investigator-initiated study; collection, management, analysis, and interpretation of the data; and preparation and review of the manuscript; however, Takeda Oncology and the TBCRC Executive Committee did approve the final draft of the manuscript.</p>
                <p content-type="data-sharing-statement"><bold>Data Sharing Statement:</bold> See <xref rid="note-COI220102-1-s" ref-type="supplementary-material">Supplement 3</xref>.</p>
                <p><bold>Meeting Presentation:</bold> This study was presented virtually at the 2020 Annual Meeting of the San Antonio Breast Cancer Symposium; December 8, 2020; San Antonio, Texas.</p>
                <p><bold>Additional Contributions:</bold> We thank all the patients who generously volunteered to participate in this study. We thank the TBCRC central office, as well as the investigators, research nurses, and study coordinators at each site, for their support of the patients and integrity with the research procedures. We thank Melissa Schardt, BS, for her administrative assistance preparing the manuscript, for which she did not receive any compensation.</p>
              </author-notes>
              <pub-date pub-type="epub" iso-8601-date="2023-03-09T10:00">
                <day>9</day>
                <month>3</month>
                <year>2023</year>
              </pub-date>
              <pub-date pub-type="ppub">
                <month>6</month>
                <year>2023</year>
              </pub-date>
              <pub-date pub-type="pmc-release">
                <day>9</day>
                <month>3</month>
                <year>2023</year>
              </pub-date>
              <!--PMC Release delay is 0 months and 0 days and was based on the <pub-date pub-type="epub"/>.-->
              <volume>9</volume>
              <issue>6</issue>
              <fpage>815</fpage>
              <lpage>824</lpage>
              <history>
                <date date-type="received">
                  <day>22</day>
                  <month>8</month>
                  <year>2022</year>
                </date>
                <date date-type="accepted">
                  <day>23</day>
                  <month>11</month>
                  <year>2022</year>
                </date>
              </history>
              <permissions>
                <copyright-statement>Copyright 2023 Haddad TC et al. <italic>JAMA Oncology</italic>.</copyright-statement>
                <license>
                  <ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref>
                  <license-p>This is an open access article distributed under the terms of the CC-BY License.</license-p>
                </license>
              </permissions>
              <self-uri content-type="pdf-version" xlink:href="jamaoncol-e227949.pdf">jamaoncol-e227949.pdf</self-uri>
              <self-uri content-type="silverchair" xlink:href="https://jamanetwork.com/journals/oncology/fullarticle/10.1001/jamaoncol.2022.7949"/>
              <abstract abstract-type="key-points">
                <title>Key Points</title>
                <sec id="ab-coi220102-1">
                  <title>Question</title>
                  <p>Does treatment with alisertib restore fulvestrant sensitivity and improve tumor objective response rates (ORRs) compared with alisertib monotherapy in patients with endocrine-resistant metastatic breast cancer?</p>
                </sec>
                <sec id="ab-coi220102-2">
                  <title>Findings</title>
                  <p>In this phase 2 randomized clinical trial of 91 patients with endocrine-resistant, metastatic breast cancer who were previously treated with a cyclin-dependent kinase 4/6 inhibitor, participants were randomized to receive treatment with alisertib alone or combined with fulvestrant. The ORR was not significantly improved by the addition of fulvestrant to alisertib, with an ORR of approximately 20.0% for both regimens.</p>
                </sec>
                <sec id="ab-coi220102-3">
                  <title>Meaning</title>
                  <p>The trial results found that while alisertib did not restore fulvestrant sensitivity and increase ORRs, promising clinical activity was observed with alisertib monotherapy among patients with endocrine-resistant and cyclin-dependent kinase 4/6 inhibitor–resistant metastatic breast cancer.</p>
                </sec>
              </abstract>
              <abstract>
                <sec id="ab-coi220102-4">
                  <title>Importance</title>
                  <p>Aurora A kinase (AURKA) activation, related in part to <italic>AURKA</italic> amplification and variants, is associated with downregulation of estrogen receptor (ER) α expression, endocrine resistance, and implicated in cyclin-dependent kinase 4/6 inhibitor (CDK 4/6i) resistance. Alisertib, a selective AURKA inhibitor, upregulates ERα and restores endocrine sensitivity in preclinical metastatic breast cancer (MBC) models. The safety and preliminary efficacy of alisertib was demonstrated in early-phase trials; however, its activity in CDK 4/6i–resistant MBC is unknown.</p>
                </sec>
                <sec id="ab-coi220102-5">
                  <title>Objective</title>
                  <p>To assess the effect of adding fulvestrant to alisertib on objective tumor response rates (ORRs) in endocrine-resistant MBC.</p>
                </sec>
                <sec id="ab-coi220102-6">
                  <title>Design, Setting, and Participants</title>
                  <p>This phase 2 randomized clinical trial was conducted through the Translational Breast Cancer Research Consortium, which enrolled participants from July 2017 to November 2019. Postmenopausal women with endocrine-resistant, ERBB2 (formerly HER2)–negative MBC who were previously treated with fulvestrant were eligible. Stratification factors included prior treatment with CDK 4/6i, baseline metastatic tumor ERα level measurement (&lt;10%, ≥10%), and primary or secondary endocrine resistance. Among 114 preregistered patients, 96 (84.2%) registered and 91 (79.8%) were evaluable for the primary end point. Data analysis began after January 10, 2022.</p>
                </sec>
                <sec id="ab-coi220102-7">
                  <title>Interventions</title>
                  <p>Alisertib, 50 mg, oral, daily on days 1 to 3, 8 to 10, and 15 to 17 of a 28-day cycle (arm 1) or alisertib same dose/schedule with standard-dose fulvestrant (arm 2).</p>
                </sec>
                <sec id="ab-coi220102-8">
                  <title>Main Outcomes and Measures</title>
                  <p>Improvement in ORR in arm 2 of at least 20% greater than arm 1 when the expected ORR for arm 1 was 20%.</p>
                </sec>
                <sec id="ab-coi220102-9">
                  <title>Results</title>
                  <p>All 91 evaluable patients (mean [SD] age, 58.5 [11.3] years; 1 American Indian/Alaskan Native [1.1%], 2 Asian [2.2%], 6 Black/African American [6.6%], 5 Hispanic [5.5%], and 79 [86.8%] White individuals; arm 1, 46 [50.5%]; arm 2, 45 [49.5%]) had received prior treatment with CDK 4/6i. The ORR was 19.6%; (90% CI, 10.6%-31.7%) for arm 1 and 20.0% (90% CI, 10.9%-32.3%) for arm 2. In arm 1, the 24-week clinical benefit rate and median progression-free survival time were 41.3% (90% CI, 29.0%-54.5%) and 5.6 months (95% CI, 3.9-10.0), respectively, and in arm 2 they were 28.9% (90% CI, 18.0%-42.0%) and 5.4 months (95% CI, 3.9-7.8), respectively. The most common grade 3 or higher adverse events attributed to alisertib were neutropenia (41.8%) and anemia (13.2%). Reasons for discontinuing treatment were disease progression (arm 1, 38 [82.6%]; arm 2, 31 [68.9%]) and toxic effects or refusal (arm 1, 5 [10.9%]; arm 2, 12 [26.7%]).</p>
                </sec>
                <sec id="ab-coi220102-10">
                  <title>Conclusions and Relevance</title>
                  <p>This randomized clinical trial found that adding fulvestrant to treatment with alisertib did not increase ORR or PFS; however, promising clinical activity was observed with alisertib monotherapy among patients with endocrine-resistant and CDK 4/6i–resistant MBC. The overall safety profile was tolerable.</p>
                </sec>
                <sec id="ab-coi220102-11">
                  <title>Trial Registration</title>
                  <p>ClinicalTrials.gov Identifier: <ext-link xlink:href="https://clinicaltrials.gov/ct2/show/NCT02860000" ext-link-type="uri">NCT02860000</ext-link></p>
                </sec>
              </abstract>
              <abstract abstract-type="teaser" specific-use="electronic">
                <p>This randomized clinical trial examines the effect of adding fulvestrant to alisertib on objective tumor response rates in endocrine-resistant metastatic breast cancer.</p>
              </abstract>
            </article-meta>
          </front>
          <body>
            <sec id="H1-1-COI220102">
              <title>Introduction</title>
              <p>Effective approaches to overcome endocrine therapy (ET) resistance remain a major challenge in estrogen receptor (ER)–positive breast cancer management.<sup><xref rid="coi220102r1" ref-type="bibr">1</xref></sup> Loss of ERα expression, a mechanism of ET resistance, is associated with tumor progression and poor clinical outcomes.<sup><xref rid="coi220102r1" ref-type="bibr">1</xref>,<xref rid="coi220102r2" ref-type="bibr">2</xref>,<xref rid="coi220102r3" ref-type="bibr">3</xref>,<xref rid="coi220102r4" ref-type="bibr">4</xref></sup></p>
              <p>We have previously demonstrated in luminal ER<sup>+</sup> breast cancer models that Aurora A kinase (AURKA) activation induces epithelial to mesenchymal transition reprogramming and clonal expansion of CD44<sup>+</sup>/CD24<sup>low/−</sup> cells with stemness features and the ability to self-renew and propagate distant metastasis.<sup><xref rid="coi220102r5" ref-type="bibr">5</xref></sup> Furthermore, these cells are characterized by loss of ERα expression and resistance to ET.<sup><xref rid="coi220102r6" ref-type="bibr">6</xref></sup> In tamoxifen-resistant ER<sup>+</sup> breast cancer models, the selective AURKA inhibitor, alisertib, was found to restore a CD44<sup>−</sup>/CD24<sup>+</sup> epithelial phenotype, ERα expression, and sensitivity to ET.<sup><xref rid="coi220102r5" ref-type="bibr">5</xref>,<xref rid="coi220102r6" ref-type="bibr">6</xref></sup> AURKA further emerged as a novel therapeutic target in kinase inhibitor screens given its association with ET resistance<sup><xref rid="coi220102r7" ref-type="bibr">7</xref>,<xref rid="coi220102r8" ref-type="bibr">8</xref></sup> and shorter disease-free and overall survival (OS) when expressed at high levels in ER<sup>+</sup> tumor biospecimens.<sup><xref rid="coi220102r9" ref-type="bibr">9</xref></sup></p>
              <p>Alisertib’s safety and tolerability profile was well-defined in early phase trials in hematologic cancers.<sup><xref rid="coi220102r10" ref-type="bibr">10</xref>,<xref rid="coi220102r11" ref-type="bibr">11</xref>,<xref rid="coi220102r12" ref-type="bibr">12</xref></sup> In a phase 2 basket trial of alisertib monotherapy for solid tumors, among those with heavily pretreated, ER<sup>+</sup>/ERBB2<sup>−</sup> (formerly HER2) metastatic breast cancer (MBC) (n = 26), a 23% objective tumor response rate (ORR), 6-month clinical benefit rate (CBR) of 54%, and median progression-free survival (mPFS) of 7.9 months were observed.<sup><xref rid="coi220102r13" ref-type="bibr">13</xref></sup></p>
              <p>Based on our preclinical rationale, we conducted a phase 1 trial combining alisertib with fulvestrant in patients who previously received aromatase inhibitor (AI) therapy for ER<sup>+</sup>/ERBB2<sup>−</sup> MBC.<sup><xref rid="coi220102r14" ref-type="bibr">14</xref></sup> A 28-day, pulse dose alisertib regimen<sup><xref rid="coi220102r15" ref-type="bibr">15</xref></sup> was used to align with the fulvestrant schedule and reduce myelosuppression. A favorable safety profile and promising clinical activity was observed, with a 6-month CBR of 78% and mPFS of 12.4 months in this cyclin-dependent kinase 4/6 inhibitor (CDK 4/6i)–naive cohort.</p>
              <p>Concurrent with alisertib development for MBC, the CDK 4/6is were established as optimal first or second-line therapies in combination with ET for ER<sup>+</sup>/ERBB2<sup>−</sup> MBC.<sup><xref rid="coi220102r16" ref-type="bibr">16</xref></sup> Despite substantial clinical improvements gained by this targeted treatment approach, CDK 4/6i resistance eventually ensues, and subsequent treatment with an AI or fulvestrant has been associated with a limited mPFS of 1.9 months in this setting.<sup><xref rid="coi220102r17" ref-type="bibr">17</xref></sup> Optimal treatment after CDK4/6i progression remains poorly defined. AURKA amplification and variants have been associated with resistance to CDK 4/6i.<sup><xref rid="coi220102r18" ref-type="bibr">18</xref>,<xref rid="coi220102r19" ref-type="bibr">19</xref></sup> However, as prior trials with alisertib did not include CDK 4/6i–resistant patients, the safety and efficacy of alisertib in this setting was unknown.</p>
              <p>Given the phase 1 results and potential importance of AURKA in the setting of endocrine and CDK 4/6i resistance, we conducted an investigator-initiated, multicenter, randomized phase 2 clinical trial to evaluate alisertib alone or combined with fulvestrant in patients with endocrine-resistant, ERBB2<sup>−</sup> MBC. The primary objective of this study was to determine if the addition of fulvestrant to treatment with alisertib could improve ORRs in fulvestrant-resistant disease.</p>
            </sec>
            <sec id="H1-2-COI220102">
              <title>Methods</title>
              <sec id="H2-1-COI220102">
                <title>Study Approval and Patient Eligibility</title>
                <p>This protocol was approved by the Mayo Clinic institutional review board and each site institutional review board within the participating Translational Breast Cancer Research Consortium (TBCRC) institutions (<xref rid="note-COI220102-1-s" ref-type="supplementary-material">Supplement 1</xref>). Participants provided written informed consent. Postmenopausal women with ER<sup>+</sup>/ERBB2<sup>−</sup> MBC or ER<sup>−</sup>/ERBB2<sup>−</sup> MBC with a history of primary ER<sup>+</sup>/ERBB2<sup>−</sup> disease were preregistered. The study defined ER<sup>+</sup> disease (by clinical assay) as 10% or more cells positive to limit inclusion of basal-like ER<sup>−</sup>/ERBB2<sup>−</sup> MBC that did not acquire ET resistance due to ERα downregulation. Additional key preregistration criteria included 2 or fewer prior MBC chemotherapy regimens, prior treatment with fulvestrant for ER<sup>+</sup> MBC, measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) criteria, willingness to limit daily alcohol intake, and no visceral crisis. Unlimited prior treatment with ET was allowed.</p>
                <p>During the preregistration period, a biopsy specimen of a metastatic site was obtained for central ERα testing (for stratification). Key registration criteria included adequate blood cell counts and chemistry results, an Eastern Cooperative Oncology Group (ECOG) performance score of 0 to 1, no systemic therapy 21 days or fewer before registration, no need for treatment with a chronic proton pump inhibitor or H2 antagonist, and no visceral crisis.</p>
              </sec>
              <sec id="H2-2-COI220102">
                <title>Study Design</title>
                <sec id="H3-1-COI220102">
                  <title>Registration and Stratification</title>
                  <p>Patients were randomized 1:1 to arm 1 (alisertib) or arm 2 (alisertib and fulvestrant). Treatment was assigned using Pocock-Simon dynamic allocation procedure<sup><xref rid="coi220102r20" ref-type="bibr">20</xref></sup> with stratification factors: ET resistance (primary vs secondary),<sup><xref rid="coi220102r21" ref-type="bibr">21</xref></sup> central laboratory ERα expression (positive vs negative), and prior treatment with CDK 4/6i (yes vs no).</p>
                </sec>
                <sec id="H3-2-COI220102">
                  <title>Treatment Schedule</title>
                  <p>Alisertib was administered as 50 mg, oral, twice daily on days 1 to 3, 8 to 10, and 15 to 17 of a 28-day cycle. Fulvestrant was administered as 500 mg, intramuscularly on days 1 and 15 of a 28-day cycle (cycle 1) and then day 1 of all subsequent cycles.</p>
                  <p>Arm 1 patients experiencing progression of disease (PD) could crossover to arm 2 if (1) ER was 10%or greater positive in preregistration or PD tumor tissue; (2) recovery from toxic effects to grade 0 to 1; (3) adequate blood cell counts and chemistry results; and (4) treatment initiated within 35 days of PD.</p>
                </sec>
                <sec id="H3-3-COI220102">
                  <title>Patient Safety and Efficacy Evaluations</title>
                  <p>Adverse events (AEs) were documented using Common Terminology Criteria for Adverse Events, version 4. Alisertib dose levels/modifications are provided in eTable 1 in <xref rid="note-COI220102-1-s" ref-type="supplementary-material">Supplement 2</xref>. Fulvestrant was not modified for AEs. If treatment with alisertib was paused due to toxic effects, then so was fulvestrant.</p>
                  <p>Within 14 days of registration, before each cycle, and at PD, patients underwent toxic effect assessments. Tumor assessments were performed after every 2 cycles.</p>
                </sec>
              </sec>
              <sec id="H2-3-COI220102">
                <title>Correlative Tissue and Blood Biospecimens</title>
                <p>Metastatic tumor biospecimens were collected during preregistration, end of cycle 1, and PD. Two tissue cores were formalin fixed and paraffin embedded while 1 core was immediately frozen at −70 °F. Formalin-fixed and paraffin-embedded tissues were sectioned at 5 microns and immunohistochemistry (IHC) staining performed using the ERα antibody, prediluted, clone SP1 (Ventana) and total AURKA antibody, diluted 1:100, clone JLM28 (Leica Microsystems).</p>
              </sec>
              <sec id="H2-4-COI220102">
                <title>Statistical Design and Analysis Plan</title>
                <p>A 2-stage, randomized phase 2 clinical trial design<sup><xref rid="coi220102r22" ref-type="bibr">22</xref></sup> with a prospective control treatment and futility stopping rule was used to assess whether the ORR with the addition of fulvestrant to alisertib was greater than alisertib alone by at least 20%, assuming the ORR for alisertib is 20%.<sup><xref rid="coi220102r13" ref-type="bibr">13</xref></sup> The ORR was defined as the percentage of patients with a complete or partial response by RECIST criteria on 2 consecutive evaluations at least 8 weeks apart. In the first stage, 28 patients were randomized to each arm, and if the combination therapy had 1 or fewer tumor responses than alisertib monotherapy, then the trial was closed to enrollment. Otherwise, an additional 17 patients were randomized to each arm. If there were 4 or more tumor responses among 45 patients who were receiving combination therapy, then we concluded that the ORR in that arm was at least 20% greater than with alisertib alone. The decision rules were chosen so that type 1 and 2 errors were 0.15. The type I error rate was relaxed for ORR and 24-week CBR as the goal was to uncover signals of benefit in support of further testing in this patient population. All registered, eligible patients who began treatment were included in the analysis cohorts according to their assigned arm.</p>
                <sec id="H3-4-COI220102">
                  <title>Secondary End Points</title>
                  <p>The 24-week CBR was defined as the percentage of patients who completed 6 cycles of treatment without PD. A 90% binomial confidence interval of the CBR was constructed. The duration of response (DoR) was measured from the date of complete or partial response to the date of PD or death, whichever was earlier. Progression-free survival was defined as time from randomization to PD or death. Overall survival was defined as time from randomization to any-cause death. The distributions of PFS and OS times were estimated with the Kaplan-Meier method.</p>
                </sec>
                <sec id="H3-5-COI220102">
                  <title>Correlative End Points</title>
                  <p>Preregistration metastatic tumor biopsy specimens were evaluated for AURKA expression (negative expression defined as 0%-10% of tumor cells with IHC staining present) and ERα expression (negative expression defined as &lt;10% of tumor cells with IHC staining present). Cox modeling was used to explore whether PFS differed in either treatment arm regarding preregistration tumor AURKA expression or ERα expression.</p>
                </sec>
                <sec id="H3-6-COI220102">
                  <title>Analysis</title>
                  <p>Data lock occurred on January 10, 2022. Analyses were conducted using SAS, version 9.4 (SAS Institute).</p>
                </sec>
              </sec>
              <sec id="H2-5-COI220102">
                <title>Study Monitoring</title>
                <p>The Mayo Clinic Comprehensive Cancer Center data safety and monitoring board monitored the trial every 6 months. The safety stopping rules applied to each arm separately. If 3 or more of the first 10 patients or 30% or more of patients randomized to the arm thereafter developed a grade 4 toxic effect that was possibly, probably, or definitely related to treatment, then enrollment would be temporarily suspended until the study chair and biostatistician recommendations were approved by coinvestigators.</p>
              </sec>
            </sec>
            <sec id="H1-3-COI220102">
              <title>Results</title>
              <p>The trial activated at the Mayo Clinic on July 6, 2017, and at the 8 participating TBCRC sites beginning February 19, 2018. Enrollment was suspended April 2, 2018, after tolerability issues were identified. Five of the initial 12 patients had grade 4 or higher AEs, among which 4 were attributed as at least possibly related to alisertib (neutropenia [2], hemolysis [1], and acute respiratory failure [1]). In response, eligibility criteria were modified to limit those with end-organ damage, central nervous system metastasis, or an ECOG performance score greater than 1 from participating (eTable 2 in <xref rid="note-COI220102-1-s" ref-type="supplementary-material">Supplement 2</xref>). The study reopened to enrollment from June 13, 2018, to November 27, 2019, during which no major safety issues were encountered and accrual goals were met.</p>
              <sec id="H2-6-COI220102">
                <title>Trial Cohort</title>
                <p>Among 114 patients who preregistered, 18 (15.8%) did not proceed to registration (<xref rid="coi220102f1" ref-type="fig">Figure 1</xref>). Of 96 patients registered, 5 (5.2%) were nonevaluable for the primary end point. The remaining 91 patients comprised the analysis cohort. Patient and disease characteristics are presented in <xref rid="coi220102t1" ref-type="table">Table 1</xref>. Of note, 91 (100%) received prior treatment with CDK 4/6i, 53 (58.2%) received prior chemotherapy for MBC, and all those with ER<sup>+</sup> MBC received prior treatment with fulvestrant.</p>
                <fig position="float" id="coi220102f1" fig-type="figure">
                  <label>Figure 1. </label>
                  <caption>
                    <title>Consolidated Standards of Reporting Trials Diagram</title>
                    <p>Patient flow from preregistration through registration/randomization and creation of the analytic cohort. BC indicates breast cancer.</p>
                  </caption>
                  <graphic xlink:href="jamaoncol-e227949-g001" position="float"/>
                </fig>
                <table-wrap position="float" id="coi220102t1">
                  <label>Table 1. </label>
                  <caption>
                    <title>Patient Characteristics</title>
                  </caption>
                  <table frame="hsides" rules="groups">
                    <col width="50.01%" span="1"/>
                    <col width="23.98%" span="1"/>
                    <col width="26.01%" span="1"/>
                    <thead>
                      <tr>
                        <th rowspan="2" valign="top" align="left" scope="col" colspan="1">Characteristic</th>
                        <th colspan="2" valign="top" align="left" scope="colgroup" rowspan="1">No. (%)</th>
                      </tr>
                      <tr>
                        <th valign="top" colspan="1" align="left" scope="colgroup" rowspan="1">Arm 1: alisertib (n = 46)</th>
                        <th valign="top" align="left" scope="col" rowspan="1" colspan="1">Arm 2: alisertib + fulvestrant (n = 45)</th>
                      </tr>
                    </thead>
                    <tbody>
                      <tr>
                        <td valign="top" align="left" scope="col" rowspan="1" colspan="1">Age, y</td>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> 18-39</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">3 (6.5)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">4 (8.9)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> 40-59</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">14 (30.4)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">20 (44.4)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> 60-74</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">25 (54.4)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">19 (42.2)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> ≥75</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">4 (8.7)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">2 (4.4)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="col" rowspan="1" colspan="1">Race</td>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> American Indian/Alaskan Native</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">0</td>
                        <td valign="top" align="left" rowspan="1" colspan="1"> 1 (2.2)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Asian</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">2 (4.4)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">0</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Black/African American</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">3 (6.5)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">3 (6.7)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> White</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">40 (87.0)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">39 (86.7)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Not reported</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">1 (2.2)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">2 (4.4)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1">Hispanic ethnicity</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">1 (2.2)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">4 (8.9)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="col" rowspan="1" colspan="1">BMI</td>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Underweight</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">0</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">1 (2.2)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Normal</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">14 (30.4)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">21 (46.7)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Overweight</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">13 (28.3)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">15 (33.3)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Obesity</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">19 (41.3)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">8 (17.8)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="col" rowspan="1" colspan="1">ECOG performance status</td>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> 0</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">30 (65.2)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">27 (60.0)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> 1</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">16 (34.8)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">18 (40.0)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="col" rowspan="1" colspan="1">Any prior chemotherapy</td>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> (Neo)adjuvant setting</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">27 (58.7)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">27 (60.0)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Metastatic setting</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">22 (47.8)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">31 (68.9)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="col" rowspan="1" colspan="1">Prior lines of chemotherapy in MBC</td>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> 0</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">24 (52.1)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">14 (31.1)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> 1</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">9 (19.6)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">19 (42.2)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> 2</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">13 (28.3)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">12 (26.7)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="col" rowspan="1" colspan="1">Any prior endocrine therapy</td>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> (Neo)adjuvant setting</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">31 (67.4)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">29 (64.4)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Metastatic setting</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">46 (100)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">45 (100)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="col" rowspan="1" colspan="1">Prior (neo)adjuvant endocrine therapy</td>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Anastrozole</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">16 (34.8)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">15 (33.3)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Exemestane</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">4 (8.7)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">5 (11.1)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Fulvestrant</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">7 (15.2)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">2 (4.4)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Letrozole</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">10 (21.7)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">6 (13.3)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Raloxifene</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">1 (2.2)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">0</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Tamoxifen</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">15 (32.6)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">22 (48.9)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="col" rowspan="1" colspan="1">Prior MBC endocrine therapy</td>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Amcenestrant</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">1 (2.2)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">0</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Anastrozole</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">8 (17.4)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">4 (8.9)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Exemestane</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">16 (34.8)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">26 (57.8)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Fulvestrant</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">45 (97.8)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">45 (100)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Letrozole</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">21 (45.7)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">33 (73.3)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Tamoxifen</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">12 (26.1)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">10 (22.2)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1">Prior CDK 4/6 inhibitor treatment</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">46 (100)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">45 (100)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="col" rowspan="1" colspan="1">Prior everolimus treatment</td>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Yes</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">17 (37.0)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">26 (57.8)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> No</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">29 (63.0)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">19 (42.2)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="col" rowspan="1" colspan="1">Endocrine resistance</td>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Primary</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">11 (23.9)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">8 (17.8)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Secondary</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">35 (76.1)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">37 (82.2)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="col" rowspan="1" colspan="1">Metastatic sites of disease</td>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Nonvisceral</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">14 (31.1)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">10 (22.2)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Visceral</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">31 (68.9)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">35 (77.8)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="col" rowspan="1" colspan="1">Metastatic tumor ERα expression</td>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Positive (≥10%)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">32 (69.6)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">31 (68.9)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Borderline (1%-9.9%)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">3 (6.5)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">4 (13.1)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Negative</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">5 (10.9)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">3 (6.7)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Insufficient tissue</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">6 (13.0)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">7 (15.6)</td>
                      </tr>
                    </tbody>
                  </table>
                  <table-wrap-foot>
                    <p>Abbreviations: BMI, body mass index (calculated as weight in kilograms divided by height in meters squared); CDK, cyclin-dependent kinase; ER, estrogen receptor; MBC, metastatic breast cancer.</p>
                  </table-wrap-foot>
                </table-wrap>
              </sec>
              <sec id="H2-7-COI220102">
                <title>Safety and Efficacy Analysis</title>
                <sec id="H3-7-COI220102">
                  <title>Arm 1: Alisertib</title>
                  <p>Three of 46 patients continued to receive alisertib as of the data lock. Reasons for discontinuing treatment included PD (38 [82.6%]), intolerability (2 [4.3%]), death (2 [4.3%]), and physician decision (1 [2.2%]). The median treatment cycles completed was 6 (range, 1-34). Seventeen patients (37.0%) required at least 1 dose reduction during the first year, most commonly due to neutropenia and anemia. The most common grade 3 or higher toxic effects were neutropenia (20 [43.4%]), leukopenia (8 [17.4%]), and anemia (9 [19.6%]). <xref rid="coi220102t2" ref-type="table">Table 2</xref> summarizes treatment-related toxic effects.</p>
                  <table-wrap position="float" id="coi220102t2">
                    <label>Table 2. </label>
                    <caption>
                      <title>Treatment-Related Adverse Events by Treatment Arm<xref rid="coi220102t2n1" ref-type="table-fn"><sup>a</sup></xref></title>
                    </caption>
                    <table frame="hsides" rules="groups">
                      <col width="36.47%" span="1"/>
                      <col width="10.42%" span="1"/>
                      <col width="17.72%" span="1"/>
                      <col width="17.72%" span="1"/>
                      <col width="17.67%" span="1"/>
                      <thead>
                        <tr>
                          <th rowspan="2" valign="top" align="left" scope="col" colspan="1">Adverse events</th>
                          <th rowspan="2" valign="top" align="left" scope="col" colspan="1">Arm<xref rid="coi220102t2n3" ref-type="table-fn"><sup>c</sup></xref></th>
                          <th colspan="3" valign="top" align="left" scope="colgroup" rowspan="1">No. (%)<xref rid="coi220102t2n2" ref-type="table-fn"><sup>b</sup></xref></th>
                        </tr>
                        <tr>
                          <th valign="top" colspan="1" align="left" scope="colgroup" rowspan="1">Grade 2</th>
                          <th valign="top" align="left" scope="col" rowspan="1" colspan="1">Grade 3</th>
                          <th valign="top" align="left" scope="col" rowspan="1" colspan="1">Grade 4</th>
                        </tr>
                      </thead>
                      <tbody>
                        <tr>
                          <td rowspan="2" valign="top" align="left" scope="row" colspan="1">Neutrophil count decreased</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">1</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">7 (15)</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">11 (24)</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">8 (17)</td>
                        </tr>
                        <tr>
                          <td valign="top" colspan="1" align="left" scope="row" rowspan="1">2</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">6 (13)</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">9 (20)</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">10 (22)</td>
                        </tr>
                        <tr>
                          <td rowspan="2" valign="top" align="left" scope="row" colspan="1">White blood cell decreased</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">1</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">13 (28)</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">6 (13)</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">2 (4)</td>
                        </tr>
                        <tr>
                          <td valign="top" colspan="1" align="left" scope="row" rowspan="1">2</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">8 (18)</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">10 (22)</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">4 (9)</td>
                        </tr>
                        <tr>
                          <td rowspan="2" valign="top" align="left" scope="row" colspan="1">Alopecia</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">1</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">19 (41)</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">0</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">0</td>
                        </tr>
                        <tr>
                          <td valign="top" colspan="1" align="left" scope="row" rowspan="1">2</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">18 (40)</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">0</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">0</td>
                        </tr>
                        <tr>
                          <td rowspan="2" valign="top" align="left" scope="row" colspan="1">Anemia</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">1</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">10 (22)</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">7 (15)</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">1 (2)</td>
                        </tr>
                        <tr>
                          <td valign="top" colspan="1" align="left" scope="row" rowspan="1">2</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">10 (22)</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">4 (9)</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">0</td>
                        </tr>
                        <tr>
                          <td rowspan="2" valign="top" align="left" scope="row" colspan="1">Fatigue</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">1</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">11 (24)</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">0</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">0</td>
                        </tr>
                        <tr>
                          <td valign="top" colspan="1" align="left" scope="row" rowspan="1">2</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">13 (29)</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">4 (9)</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">0</td>
                        </tr>
                        <tr>
                          <td rowspan="2" valign="top" align="left" scope="row" colspan="1">Lymphocyte count decreased</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">1</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">5 (11)</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">2 (4)</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">0</td>
                        </tr>
                        <tr>
                          <td valign="top" colspan="1" align="left" scope="row" rowspan="1">2</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">5 (11)</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">6 (13)</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">0</td>
                        </tr>
                        <tr>
                          <td rowspan="2" valign="top" align="left" scope="row" colspan="1">Anorexia</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">1</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">7 (15)</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">0</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">0</td>
                        </tr>
                        <tr>
                          <td valign="top" colspan="1" align="left" scope="row" rowspan="1">2</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">3 (7)</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">1 (2)</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">0</td>
                        </tr>
                        <tr>
                          <td rowspan="2" valign="top" align="left" scope="row" colspan="1">Platelet count decreased</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">1</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">2 (4)</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">2 (4)</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">1 (2)</td>
                        </tr>
                        <tr>
                          <td valign="top" colspan="1" align="left" scope="row" rowspan="1">2</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">2 (4)</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">1 (2)</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">1 (2)</td>
                        </tr>
                        <tr>
                          <td rowspan="2" valign="top" align="left" scope="row" colspan="1">Mucositis oral</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">1</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">4 (9)</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">1 (2)</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">0</td>
                        </tr>
                        <tr>
                          <td valign="top" colspan="1" align="left" scope="row" rowspan="1">2</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">1 (2)</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">1 (2)</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">0</td>
                        </tr>
                        <tr>
                          <td rowspan="2" valign="top" align="left" scope="row" colspan="1">Nausea</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">1</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">1 (2)</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">0</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">0</td>
                        </tr>
                        <tr>
                          <td valign="top" colspan="1" align="left" scope="row" rowspan="1">2</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">3 (7)</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">1 (2)</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">0</td>
                        </tr>
                        <tr>
                          <td rowspan="2" valign="top" align="left" scope="row" colspan="1">Febrile neutropenia</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">1</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">0</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">1 (2)</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">0</td>
                        </tr>
                        <tr>
                          <td valign="top" colspan="1" align="left" scope="row" rowspan="1">2</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">0</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">1 (2)</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">1 (2)</td>
                        </tr>
                        <tr>
                          <td rowspan="2" valign="top" align="left" scope="row" colspan="1">Thromboembolic event</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">1</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">0</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">0</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">0</td>
                        </tr>
                        <tr>
                          <td valign="top" colspan="1" align="left" scope="row" rowspan="1">2</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">0</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">3 (7)</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">0</td>
                        </tr>
                        <tr>
                          <td rowspan="2" valign="top" align="left" scope="row" colspan="1">Acute coronary syndrome</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">1</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">0</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">0</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">1 (2)</td>
                        </tr>
                        <tr>
                          <td valign="top" colspan="1" align="left" scope="row" rowspan="1">2</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">0</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">0</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">0</td>
                        </tr>
                        <tr>
                          <td rowspan="2" valign="top" align="left" scope="row" colspan="1">Investigations: thrombotic microangiopathic hemolysis</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">1</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">0</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">0</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">1 (2)</td>
                        </tr>
                        <tr>
                          <td valign="top" colspan="1" align="left" scope="row" rowspan="1">2</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">0</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">0</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">0</td>
                        </tr>
                      </tbody>
                    </table>
                    <table-wrap-foot>
                      <fn id="coi220102t2n1">
                        <label>
                          <sup>a</sup>
                        </label>
                        <p>One grade 5 respiratory failure that was at least possibly related to treatment occurred in arm 2.</p>
                      </fn>
                      <fn id="coi220102t2n2">
                        <label>
                          <sup>b</sup>
                        </label>
                        <p>All grade 3 to 4 adverse events at least possibly related to treatment and the most common grade 2 adverse events (&gt;10% in at least 1 treatment arm) at least possibly related to treatment were included.</p>
                      </fn>
                      <fn id="coi220102t2n3">
                        <label>
                          <sup>c</sup>
                        </label>
                        <p>Arm 1 alisertib monotherapy and arm 2 alisertib + fulvestrant.</p>
                      </fn>
                    </table-wrap-foot>
                  </table-wrap>
                  <p>Nine partial responses were observed (<xref rid="coi220102f2" ref-type="fig">Figure 2</xref>). Thus, the ORR was 19.6% (90% CI, 10.6%-31.7%). Median DoR was 15.1 months, and 24-week CBR was 41.3% (90% CI, 29.0%-54.5%). The mPFS time was estimated to be 5.6 months (95% CI, 3.9-10.0). The 1-year OS rate was 75.1% (95% CI, 63.4%-89.0%), and median OS time was estimated to be 22.7 months (95% CI, 18.4% to not estimable).</p>
                  <fig position="float" id="coi220102f2" fig-type="figure">
                    <label>Figure 2. </label>
                    <caption>
                      <title>Best Overall Tumor Response and Disease Status Over Time for Individual Patients by Treatment Arm</title>
                      <p>Waterfall plots indicate individual patient (x-axis) best tumor response as measured by percentage change from baseline (y-axis). Swimmer plots indicate individual disease status over time. Estrogen receptor (ER) α staining status is categorized by results of central review on the preregistration, metastatic site biopsy. A, Arm 1 (alisertib monotherapy) waterfall plot. B, Arm 2 (alisertib + fulvestrant) waterfall plot. C, Arm 1 (alisertib monotherapy) swimmer plot. D, Arm 2 (alisertib + fulvestrant) swimmer plot.</p>
                    </caption>
                    <graphic xlink:href="jamaoncol-e227949-g002" position="float"/>
                  </fig>
                </sec>
                <sec id="H3-8-COI220102">
                  <title>Arm 2: Alisertib + Fulvestrant</title>
                  <p>Two of 45 patients continued to receive alisertib with fulvestrant as of the data lock. Reasons for discontinuing treatment included PD (31 [68.9%]), intolerability (6 [13.3%]), refusal (4 [8.9%]), second primary cancer (1 [2.2%]), and death (1 [2.2%]). The median treatment cycles completed was 4 (range, 1-44). Sixteen patients (35.6%) required at least 1 dose reduction within the first year, most commonly due to neutropenia. Per <xref rid="coi220102t2" ref-type="table">Table 2</xref>, the most common grade 3 or higher toxic effects were neutropenia (19 [42.2%]), leukopenia (14 [31.1%]), lymphopenia (7 [15.6%]), fatigue (5 [11.1%]), and anemia (4 [8.9%]).</p>
                  <p>One complete response and 8 partial responses were observed (<xref rid="coi220102f2" ref-type="fig">Figure 2</xref>). Thus, the ORR was 20.0%; (90% CI, 10.9%-32.3%). Median DoR was 8.5 months, and 24-week CBR was 28.9% (90% CI, 18.0%-42.0%). The estimated mPFS time was 5.4 months (95% CI, 3.9-7.8). The 1-year OS rate was 62.7% (95% CI, 49.7%-79.0%), and estimated median OS time was 19.8 months (95% CI, 11.5 to not estimable).</p>
                </sec>
                <sec id="H3-9-COI220102">
                  <title>Arm 1 Crossover to Arm 2</title>
                  <p>Seventeen of 37 patients (45.9%) who experienced disease progression while taking alisertib crossed over to arm 2. This occurred mostly commonly after 2 (n = 5) or 6 cycles (n = 5) of alisertib; however, 4 patients initiated combination treatment after 17 to 26 cycles. All patients discontinued treatment due to PD after undergoing 1 to 14 cycles of combination therapy. One partial response was observed with combination treatment. The mPFS after crossover was 3.7 months.</p>
                </sec>
              </sec>
              <sec id="H2-8-COI220102">
                <title>Correlative Studies</title>
                <p>Expression levels of ERα and AURKA in the preregistration tumors were available for 70 patients (arm 1, 35; arm 2, 35) and 77 patients (arm 1, 39; arm 2, 38; <xref rid="coi220102t1" ref-type="table">Table 1</xref>), respectively. For arm 1, there was insufficient evidence to conclude that PFS differed regarding ERα expression (hazard ratio [HR], 1.79, 95% CI, 0.77%-4.19%; <xref rid="coi220102f3" ref-type="fig">Figure 3</xref>A); however, there was evidence to suggest that PFS increased for those with AURKA negative tumors compared with those with AURKA positive tumors (HR, 0.25, 95% CI, 0.10-0.62; <xref rid="coi220102f3" ref-type="fig">Figure 3</xref>C). For arm 2, there was insufficient evidence to conclude that PFS differed regarding either ERα expression (HR, 2.27, 95% CI, 0.84-6.14; <xref rid="coi220102f3" ref-type="fig">Figure 3</xref>B) or AURKA expression (HR, 0.48, 95% CI, 0.21-1.10; <xref rid="coi220102f3" ref-type="fig">Figure 3</xref>D).</p>
                <fig position="float" id="coi220102f3" fig-type="figure">
                  <label>Figure 3. </label>
                  <caption>
                    <title>Association of Baseline Metastatic Tumor Estrogen Receptor (ER) α and Aurora A Kinase (AURKA) Expression and Progression-Free Survival (PFS)</title>
                    <p>Formalin-fixed and paraffin-embedded metastatic tumor tissue blocks were sectioned and stained using antibodies against ERα or total AURKA. A log-rank test and Cox modeling were used to assess whether PFS differed regarding pretreatment metastatic tumor ERα expression of 10% or greater or AURKA expression less than 10%. A, Arm 1 (alisertib monotherapy): ERα. B, Arm 2 (alisertib + fulvestrant): ERα. C, Arm 1 (alisertib monotherapy): AURKA. D, Arm 2 (alisertib + fulvestrant): AURKA.</p>
                  </caption>
                  <graphic xlink:href="jamaoncol-e227949-g003" position="float"/>
                </fig>
              </sec>
            </sec>
            <sec id="H1-4-COI220102">
              <title>Discussion</title>
              <p>In this randomized phase 2 clinical trial, the clinical efficacy and safety of alisertib alone or combined with fulvestrant was evaluated in ERBB2<sup>−</sup> MBC. All patients received prior treatment with CDK 4/6i, and of those with ER<sup>+</sup> MBC, all received prior fulvestrant. While the addition of fulvestrant to alisertib did not improve ORR, clinically meaningful antitumor activity was observed in both arms. Among those who received alisertib, this included a confirmed ORR of 19.6%, 24-week CBR of 41.3%, mPFS of 5.6 months, and median OS of 22.7 months.</p>
              <p>These results confirm prior findings demonstrating the antitumor activity of alisertib in endocrine-resistant, ER<sup>+</sup>/ERBB2<sup>−</sup> MBC. They are comparable with those observed in prior trials with established effective agents. For example, in MONARCH-1, a phase 2 study of the CDK 4/6i abemaciclib in patients with ER<sup>+</sup> MBC that was previously treated with ET and 2 or fewer prior lines of chemotherapy, the confirmed ORR was 19.7% (95% CI, 13.3%-27.5%), 6-month CBR was 42.4%, mPFS was 6.0 months, and median OS was 17.7 months.<sup><xref rid="coi220102r23" ref-type="bibr">23</xref></sup> These findings led to the US Food and Drug Administration approval of abemaciclib as monotherapy.</p>
              <p>While caution must be applied when conducting cross-trial comparisons, to our knowledge, there is a paucity of clinical data regarding the efficacy of approved or investigational therapies following CDK 4/6i progression. Evaluating the current study results in this context may help to understand the potential value of alisertib in the evolving landscape of endocrine-resistant and CDK 4/6i–resistant MBC. Notably, single-agent ET has limited efficacy in this setting, as evidenced by the phase 2 VERONICA trial (n = 101) in which mPFS to fulvestrant was 1.94 months (95% CI, 1.84-3.55).<sup><xref rid="coi220102r24" ref-type="bibr">24</xref></sup> In the phase 3 EMERALD trial, the oral selective ER degrader elacestrant was associated with a significantly improved mPFS compared with standard ET (fulvestrant or AI); however, mPFS was only 2.8 months.<sup><xref rid="coi220102r17" ref-type="bibr">17</xref></sup></p>
              <p>In the BYLieve trial, a single-arm study of alpelisib with fulvestrant in patients with CDK 4/6i–resistant, <italic>PIK3CA</italic>-variant, ER<sup>+</sup> MBC, those with measurable disease (n = 100) had an ORR (calculated as best overall response) of 21% (95% CI, 14%-30%) and a 24-week CBR of 42% (95% CI, 35%-52%).<sup><xref rid="coi220102r25" ref-type="bibr">25</xref></sup> In the overall cohort (n = 121), including those with the more clinically favorable nonmeasurable disease, mPFS was 7.3 months; (95% CI, 5.6-8.3) and mOS was 17.3 months (95% CI, 17.2-20.7). The duration of follow-up in BYLieve was limited, and thus the OS results may be immature. Additionally, <italic>PIK3CA</italic>-variant, ER<sup>+</sup>/ERBB2<sup>−</sup> MBC is associated with shortened OS and resistance to chemotherapy compared with those with <italic>PIK3CA</italic> wild-type disease.<sup><xref rid="coi220102r26" ref-type="bibr">26</xref></sup> While alisertib was associated with comparable clinical activity observed in the BYLieve trial, its efficacy in the setting of <italic>PIK3CA</italic>-variant disease is unknown and will be explored in subsequent correlative studies.</p>
              <p>The phase 3 TROPICS-02 trial (n = 543) included patients with endocrine-resistant and CDK 4/6i–resistant MBC and reported an improvement in mPFS with the antibody drug conjugate sacituzumab govitecan (5.5 months; 95% CI, 4.2-7.0) compared with single-agent chemotherapy of the physician’s choice (4.0 months; 95% CI, 3.1-4.4).<sup><xref rid="coi220102r27" ref-type="bibr">27</xref></sup> In the phase 3 DESTINY B-04 trial, among those in the analytic cohort with hormone receptor–positive/ERBB2 (HER2)<sup>−</sup>–low disease (n = 494), all patients were endocrine resistant, and 70.4% received prior treatment with CDK 4/6i. An improvement in mPFS was reported with the antibody drug conjugate trastuzumab deruxtecan compared with single-agent chemotherapy of the physician’s choice (10.1 vs 5.4 months; HR, 0.51, 95% CI, 0.4-0.64).<sup><xref rid="coi220102r28" ref-type="bibr">28</xref></sup> Thus, the mPFS and other clinical outcomes associated with alisertib are similar to those observed in comparable patients treated with single-agent chemotherapy or sacituzumab govitecan.</p>
              <p>An increased rate of investigational therapy discontinuation for reasons other than PD was observed in this trial among those receiving combination fulvestrant and alisertib. This was unexpected given the lack of overlapping toxic effects and favorable safety profile observed in our prior phase 1 trial of combination therapy.<sup><xref rid="coi220102r14" ref-type="bibr">14</xref></sup> There were only minor differences in the most common AEs between arms. While there were more grade 3 fatigue and thromboembolic events in arm 2, they did not lead to treatment discontinuation. More patients in arm 2 than arm 1 received prior everolimus (57.8% vs 37.0%) and chemotherapy (68.9% vs 47.8%) for MBC. Thus, it is feasible that heavier pretreatment with other targeted and cytotoxic agents may have decreased tolerance to the investigational therapy. This is further strengthened by the observation that all 17 arm 1 patients who crossed over to arm 2 discontinued combination therapy due to PD, not treatment intolerance.</p>
              <p>Given the clinical efficacy and safety results observed in TBCRC 041, continued clinical development of alisertib is warranted and planned. Further supporting this is the observation of clinical activity among those who received prior everolimus. If the clinical outcomes observed in this study were confirmed in a subsequent registration trial, alisertib may provide a new treatment option for endocrine-resistant disease to a broader cohort of patients given that alpelisib is only available for <italic>PIK3CA</italic>-variant MBC, which is present only in 25% to 40% of ER<sup>+</sup>/<italic>ERBB2</italic><sup>−</sup> MBC.<sup><xref rid="coi220102r25" ref-type="bibr">25</xref>,<xref rid="coi220102r29" ref-type="bibr">29</xref></sup></p>
              <p>The correlative studies indicated that high AURKA registration tumor expression was associated with poor clinical outcomes, which was consistent with prior studies.<sup><xref rid="coi220102r9" ref-type="bibr">9</xref>,<xref rid="coi220102r30" ref-type="bibr">30</xref></sup> Additional correlative studies are under way to evaluate the role of <italic>PIK3CA</italic> variant status and assess whether pharmacodynamic-induced changes in ERα, total and phosphorylated AURKA, and other stemness biomarkers that are associated with clinical benefit from alisertib.</p>
              <p>While alisertib did not restore sensitivity to fulvestrant as preclinical studies<sup><xref rid="coi220102r5" ref-type="bibr">5</xref>,<xref rid="coi220102r6" ref-type="bibr">6</xref></sup> conducted before the CDK 4/6i era had suggested, it is feasible the hypothesis was not fairly tested given that accumulating clinical data demonstrate minimal antitumor activity of endocrine monotherapy following CDK 4/6i progression<sup><xref rid="coi220102r17" ref-type="bibr">17</xref>,<xref rid="coi220102r24" ref-type="bibr">24</xref></sup> and the fact that the entire cohort received prior CDK 4/6i therapy. Furthermore, the role of continued ER blockade in combination with targeted therapies after CDK 4/6i progression is unclear.</p>
              <sec id="H2-9-COI220102">
                <title>Limitations</title>
                <p>Limitations to this trial include a higher percentage of women with obesity who were assigned to arm 1, while a higher percentage of women who had prior exposure to chemotherapy and/or everolimus were assigned to arm 2. Obesity, with its associated comorbidities, as well as prior exposure to chemotherapy, may have negatively affected tolerability to alisertib and the ability to continue receiving treatment. Additionally, the study cohort was confined to postmenopausal women, and participation of those of racial and ethnic minority groups was suboptimal, thus limiting generalizability. Finally, the sample size for the correlative studies was small, which limits interpretation.</p>
              </sec>
            </sec>
            <sec id="H1-5-COI220102">
              <title>Conclusions</title>
              <p>This phase 2 randomized clinical trial found that alisertib is among the first investigational targeted therapies demonstrating promising clinical activity and a tolerable safety profile in the setting of endocrine and CDK 4/6i–resistant MBC.</p>
            </sec>
          </body>
          <back>
            <ref-list id="REF-COI220102">
              <title>References</title>
              <ref id="coi220102r1">
                <label>1</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Osborne</surname><given-names>CK</given-names></string-name>, <string-name><surname>Schiff</surname><given-names>R</given-names></string-name></person-group>. <article-title>Mechanisms of endocrine resistance in breast cancer</article-title>. <source>Annu Rev Med</source>. <year>2011</year>;<volume>62</volume>:<fpage>233</fpage>-<lpage>247</lpage>. doi:<pub-id pub-id-type="doi">10.1146/annurev-med-070909-182917</pub-id><?supplied-pmid 20887199?><pub-id pub-id-type="pmid">20887199</pub-id></mixed-citation>
              </ref>
              <ref id="coi220102r2">
                <label>2</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Kuukasjärvi</surname><given-names>T</given-names></string-name>, <string-name><surname>Kononen</surname><given-names>J</given-names></string-name>, <string-name><surname>Helin</surname><given-names>H</given-names></string-name>, <string-name><surname>Holli</surname><given-names>K</given-names></string-name>, <string-name><surname>Isola</surname><given-names>J</given-names></string-name></person-group>. <article-title>Loss of estrogen receptor in recurrent breast cancer is associated with poor response to endocrine therapy</article-title>. <source>J Clin Oncol</source>. <year>1996</year>;<volume>14</volume>(<issue>9</issue>):<fpage>2584</fpage>-<lpage>2589</lpage>. doi:<pub-id pub-id-type="doi">10.1200/JCO.1996.14.9.2584</pub-id><?supplied-pmid 8823339?><pub-id pub-id-type="pmid">8823339</pub-id></mixed-citation>
              </ref>
              <ref id="coi220102r3">
                <label>3</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Gutierrez</surname><given-names>MC</given-names></string-name>, <string-name><surname>Detre</surname><given-names>S</given-names></string-name>, <string-name><surname>Johnston</surname><given-names>S</given-names></string-name>, <etal/></person-group>. <article-title>Molecular changes in tamoxifen-resistant breast cancer: relationship between estrogen receptor, <italic>HER-2</italic>, and p38 mitogen-activated protein kinase</article-title>. <source>J Clin Oncol</source>. <year>2005</year>;<volume>23</volume>(<issue>11</issue>):<fpage>2469</fpage>-<lpage>2476</lpage>. doi:<pub-id pub-id-type="doi">10.1200/JCO.2005.01.172</pub-id><?supplied-pmid 15753463?><pub-id pub-id-type="pmid">15753463</pub-id></mixed-citation>
              </ref>
              <ref id="coi220102r4">
                <label>4</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Lindström</surname><given-names>LS</given-names></string-name>, <string-name><surname>Karlsson</surname><given-names>E</given-names></string-name>, <string-name><surname>Wilking</surname><given-names>UM</given-names></string-name>, <etal/></person-group>. <article-title>Clinically used breast cancer markers such as estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 are unstable throughout tumor progression</article-title>. <source>J Clin Oncol</source>. <year>2012</year>;<volume>30</volume>(<issue>21</issue>):<fpage>2601</fpage>-<lpage>2608</lpage>. doi:<pub-id pub-id-type="doi">10.1200/JCO.2011.37.2482</pub-id><?supplied-pmid 22711854?><pub-id pub-id-type="pmid">22711854</pub-id></mixed-citation>
              </ref>
              <ref id="coi220102r5">
                <label>5</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>D’Assoro</surname><given-names>AB</given-names></string-name>, <string-name><surname>Liu</surname><given-names>T</given-names></string-name>, <string-name><surname>Quatraro</surname><given-names>C</given-names></string-name>, <etal/></person-group>. <article-title>The mitotic kinase Aurora–a promotes distant metastases by inducing epithelial-to-mesenchymal transition in ERα(+) breast cancer cells</article-title>. <source>Oncogene</source>. <year>2014</year>;<volume>33</volume>(<issue>5</issue>):<fpage>599</fpage>-<lpage>610</lpage>. doi:<pub-id pub-id-type="doi">10.1038/onc.2012.628</pub-id><?supplied-pmid 23334326?><pub-id pub-id-type="pmid">23334326</pub-id></mixed-citation>
              </ref>
              <ref id="coi220102r6">
                <label>6</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Opyrchal</surname><given-names>M</given-names></string-name>, <string-name><surname>Salisbury</surname><given-names>JL</given-names></string-name>, <string-name><surname>Zhang</surname><given-names>S</given-names></string-name>, <etal/></person-group>. <article-title>Aurora-A mitotic kinase induces endocrine resistance through down-regulation of ERα expression in initially ERα+ breast cancer cells</article-title>. <source>PLoS One</source>. <year>2014</year>;<volume>9</volume>(<issue>5</issue>):<elocation-id>e96995</elocation-id>. doi:<pub-id pub-id-type="doi">10.1371/journal.pone.0096995</pub-id><?supplied-pmid 24816249?><pub-id pub-id-type="pmid">24816249</pub-id></mixed-citation>
              </ref>
              <ref id="coi220102r7">
                <label>7</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Thrane</surname><given-names>S</given-names></string-name>, <string-name><surname>Pedersen</surname><given-names>AM</given-names></string-name>, <string-name><surname>Thomsen</surname><given-names>MB</given-names></string-name>, <etal/></person-group>. <article-title>A kinase inhibitor screen identifies Mcl-1 and Aurora kinase A as novel treatment targets in antiestrogen-resistant breast cancer cells</article-title>. <source>Oncogene</source>. <year>2015</year>;<volume>34</volume>(<issue>32</issue>):<fpage>4199</fpage>-<lpage>4210</lpage>. doi:<pub-id pub-id-type="doi">10.1038/onc.2014.351</pub-id><?supplied-pmid 25362855?><pub-id pub-id-type="pmid">25362855</pub-id></mixed-citation>
              </ref>
              <ref id="coi220102r8">
                <label>8</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Hole</surname><given-names>S</given-names></string-name>, <string-name><surname>Pedersen</surname><given-names>AM</given-names></string-name>, <string-name><surname>Lykkesfeldt</surname><given-names>AE</given-names></string-name>, <string-name><surname>Yde</surname><given-names>CW</given-names></string-name></person-group>. <article-title>Aurora kinase A and B as new treatment targets in aromatase inhibitor-resistant breast cancer cells</article-title>. <source>Breast Cancer Res Treat</source>. <year>2015</year>;<volume>149</volume>(<issue>3</issue>):<fpage>715</fpage>-<lpage>726</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s10549-015-3284-8</pub-id><?supplied-pmid 25667100?><pub-id pub-id-type="pmid">25667100</pub-id></mixed-citation>
              </ref>
              <ref id="coi220102r9">
                <label>9</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Siggelkow</surname><given-names>W</given-names></string-name>, <string-name><surname>Boehm</surname><given-names>D</given-names></string-name>, <string-name><surname>Gebhard</surname><given-names>S</given-names></string-name>, <etal/></person-group>. <article-title>Expression of aurora kinase A is associated with metastasis-free survival in node-negative breast cancer patients</article-title>. <source>BMC Cancer</source>. <year>2012</year>;<volume>12</volume>:<fpage>562</fpage>. doi:<pub-id pub-id-type="doi">10.1186/1471-2407-12-562</pub-id><?supplied-pmid 23186136?><pub-id pub-id-type="pmid">23186136</pub-id></mixed-citation>
              </ref>
              <ref id="coi220102r10">
                <label>10</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Friedberg</surname><given-names>JW</given-names></string-name>, <string-name><surname>Mahadevan</surname><given-names>D</given-names></string-name>, <string-name><surname>Cebula</surname><given-names>E</given-names></string-name>, <etal/></person-group>. <article-title>Phase II study of alisertib, a selective Aurora A kinase inhibitor, in relapsed and refractory aggressive B- and T-cell non-Hodgkin lymphomas</article-title>. <source>J Clin Oncol</source>. <year>2014</year>;<volume>32</volume>(<issue>1</issue>):<fpage>44</fpage>-<lpage>50</lpage>. doi:<pub-id pub-id-type="doi">10.1200/JCO.2012.46.8793</pub-id><?supplied-pmid 24043741?><pub-id pub-id-type="pmid">24043741</pub-id></mixed-citation>
              </ref>
              <ref id="coi220102r11">
                <label>11</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Dees</surname><given-names>EC</given-names></string-name>, <string-name><surname>Cohen</surname><given-names>RB</given-names></string-name>, <string-name><surname>von Mehren</surname><given-names>M</given-names></string-name>, <etal/></person-group>. <article-title>Phase I study of aurora A kinase inhibitor MLN8237 in advanced solid tumors: safety, pharmacokinetics, pharmacodynamics, and bioavailability of two oral formulations</article-title>. <source>Clin Cancer Res</source>. <year>2012</year>;<volume>18</volume>(<issue>17</issue>):<fpage>4775</fpage>-<lpage>4784</lpage>. doi:<pub-id pub-id-type="doi">10.1158/1078-0432.CCR-12-0589</pub-id><?supplied-pmid 22767670?><pub-id pub-id-type="pmid">22767670</pub-id></mixed-citation>
              </ref>
              <ref id="coi220102r12">
                <label>12</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>D’Assoro</surname><given-names>AB</given-names></string-name>, <string-name><surname>Haddad</surname><given-names>T</given-names></string-name>, <string-name><surname>Galanis</surname><given-names>E</given-names></string-name></person-group>. <article-title>Aurora-A Kinase as a promising therapeutic target in cancer</article-title>. <source>Front Oncol</source>. <year>2016</year>;<volume>5</volume>:<fpage>295</fpage>. doi:<pub-id pub-id-type="doi">10.3389/fonc.2015.00295</pub-id><?supplied-pmid 26779440?><pub-id pub-id-type="pmid">26779440</pub-id></mixed-citation>
              </ref>
              <ref id="coi220102r13">
                <label>13</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Melichar</surname><given-names>B</given-names></string-name>, <string-name><surname>Adenis</surname><given-names>A</given-names></string-name>, <string-name><surname>Lockhart</surname><given-names>AC</given-names></string-name>, <etal/></person-group>. <article-title>Safety and activity of alisertib, an investigational aurora kinase A inhibitor, in patients with breast cancer, small-cell lung cancer, non-small-cell lung cancer, head and neck squamous-cell carcinoma, and gastro-oesophageal adenocarcinoma: a five-arm phase 2 study</article-title>. <source>Lancet Oncol</source>. <year>2015</year>;<volume>16</volume>(<issue>4</issue>):<fpage>395</fpage>-<lpage>405</lpage>. doi:<pub-id pub-id-type="doi">10.1016/S1470-2045(15)70051-3</pub-id><?supplied-pmid 25728526?><pub-id pub-id-type="pmid">25728526</pub-id></mixed-citation>
              </ref>
              <ref id="coi220102r14">
                <label>14</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Haddad</surname><given-names>TC</given-names></string-name>, <string-name><surname>D’Assoro</surname><given-names>A</given-names></string-name>, <string-name><surname>Suman</surname><given-names>V</given-names></string-name>, <etal/></person-group>. <article-title>Phase I trial to evaluate the addition of alisertib to fulvestrant in women with endocrine-resistant, ER+ metastatic breast cancer</article-title>. <source>Breast Cancer Res Treat</source>. <year>2018</year>;<volume>168</volume>(<issue>3</issue>):<fpage>639</fpage>-<lpage>647</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s10549-017-4616-7</pub-id><?supplied-pmid 29289986?><pub-id pub-id-type="pmid">29289986</pub-id></mixed-citation>
              </ref>
              <ref id="coi220102r15">
                <label>15</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Huck</surname><given-names>JJ</given-names></string-name>, <string-name><surname>Zhang</surname><given-names>M</given-names></string-name>, <string-name><surname>Mettetal</surname><given-names>J</given-names></string-name>, <etal/></person-group>. <article-title>Translational exposure-efficacy modeling to optimize the dose and schedule of taxanes combined with the investigational Aurora A kinase inhibitor MLN8237 (alisertib)</article-title>. <source>Mol Cancer Ther</source>. <year>2014</year>;<volume>13</volume>(<issue>9</issue>):<fpage>2170</fpage>-<lpage>2183</lpage>. doi:<pub-id pub-id-type="doi">10.1158/1535-7163.MCT-14-0027</pub-id><?supplied-pmid 24980948?><pub-id pub-id-type="pmid">24980948</pub-id></mixed-citation>
              </ref>
              <ref id="coi220102r16">
                <label>16</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Li</surname><given-names>J</given-names></string-name>, <string-name><surname>Huo</surname><given-names>X</given-names></string-name>, <string-name><surname>Zhao</surname><given-names>F</given-names></string-name>, <etal/></person-group>. <article-title>Association of cyclin-dependent kinases 4 and 6 inhibitors with survival in patients with hormone receptor–positive metastatic breast cancer: a systematic review and meta-analysis</article-title>. <source>JAMA Netw Open</source>. <year>2020</year>;<volume>3</volume>(<issue>10</issue>):<elocation-id>e2020312</elocation-id>. doi:<pub-id pub-id-type="doi">10.1001/jamanetworkopen.2020.20312</pub-id><?supplied-pmid 33048129?><pub-id pub-id-type="pmid">33048129</pub-id></mixed-citation>
              </ref>
              <ref id="coi220102r17">
                <label>17</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Bidard</surname><given-names>FC</given-names></string-name>, <string-name><surname>Kaklamani</surname><given-names>VG</given-names></string-name>, <string-name><surname>Neven</surname><given-names>P</given-names></string-name>, <etal/></person-group>. <article-title>Elacestrant (oral selective estrogen receptor degrader) versus standard endocrine therapy for estrogen receptor–positive, human epidermal growth factor receptor 2–negative advanced breast cancer: results from the randomized phase III EMERALD trial</article-title>. <source>J Clin Oncol</source>. <year>2022</year>;<volume>40</volume>(<issue>28</issue>):<fpage>3246</fpage>-<lpage>3256</lpage>. doi:<pub-id pub-id-type="doi">10.1200/JCO.22.00338</pub-id><?supplied-pmid 35584336?><pub-id pub-id-type="pmid">35584336</pub-id></mixed-citation>
              </ref>
              <ref id="coi220102r18">
                <label>18</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Wander</surname><given-names>SA</given-names></string-name>, <string-name><surname>Cohen</surname><given-names>O</given-names></string-name>, <string-name><surname>Gong</surname><given-names>X</given-names></string-name>, <etal/></person-group>. <article-title>The genomic landscape of intrinsic and acquired resistance to cyclin-dependent kinase 4/6 inhibitors in patients with hormone receptor–positive metastatic breast cancer</article-title>. <source>Cancer Discov</source>. <year>2020</year>;<volume>10</volume>(<issue>8</issue>):<fpage>1174</fpage>-<lpage>1193</lpage>. doi:<pub-id pub-id-type="doi">10.1158/2159-8290.CD-19-1390</pub-id><?supplied-pmid 32404308?><pub-id pub-id-type="pmid">32404308</pub-id></mixed-citation>
              </ref>
              <ref id="coi220102r19">
                <label>19</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Elfgen</surname><given-names>C</given-names></string-name>, <string-name><surname>Bjelic-Radisic</surname><given-names>V</given-names></string-name></person-group>. <article-title>Targeted therapy in HR+ <italic>HER2</italic>− metastatic breast cancer: current clinical trials and their implications for CDK4/6 inhibitor therapy and beyond treatment options</article-title>. <source>Cancers (Basel)</source>. <year>2021</year>;<volume>13</volume>(<issue>23</issue>):<fpage>5994</fpage>. doi:<pub-id pub-id-type="doi">10.3390/cancers13235994</pub-id><?supplied-pmid 34885105?><pub-id pub-id-type="pmid">34885105</pub-id></mixed-citation>
              </ref>
              <ref id="coi220102r20">
                <label>20</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Pocock</surname><given-names>SJ</given-names></string-name>, <string-name><surname>Simon</surname><given-names>R</given-names></string-name></person-group>. <article-title>Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial</article-title>. <source>Biometrics</source>. <year>1975</year>;<volume>31</volume>(<issue>1</issue>):<fpage>103</fpage>-<lpage>115</lpage>. doi:<pub-id pub-id-type="doi">10.2307/2529712</pub-id><?supplied-pmid 1100130?><pub-id pub-id-type="pmid">1100130</pub-id></mixed-citation>
              </ref>
              <ref id="coi220102r21">
                <label>21</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Cardoso</surname><given-names>F</given-names></string-name>, <string-name><surname>Senkus</surname><given-names>E</given-names></string-name>, <string-name><surname>Costa</surname><given-names>A</given-names></string-name>, <etal/></person-group>. <article-title>4th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 4)</article-title>. <source>Ann Oncol</source>. <year>2018</year>;<volume>29</volume>(<issue>8</issue>):<fpage>1634</fpage>-<lpage>1657</lpage>. doi:<pub-id pub-id-type="doi">10.1093/annonc/mdy192</pub-id><?supplied-pmid 30032243?><pub-id pub-id-type="pmid">30032243</pub-id></mixed-citation>
              </ref>
              <ref id="coi220102r22">
                <label>22</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Jung</surname><given-names>SH</given-names></string-name></person-group>. <article-title>Randomized phase II trials with a prospective control</article-title>. <source>Stat Med</source>. <year>2008</year>;<volume>27</volume>(<issue>4</issue>):<fpage>568</fpage>-<lpage>583</lpage>. doi:<pub-id pub-id-type="doi">10.1002/sim.2961</pub-id><?supplied-pmid 17573688?><pub-id pub-id-type="pmid">17573688</pub-id></mixed-citation>
              </ref>
              <ref id="coi220102r23">
                <label>23</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Dickler</surname><given-names>MN</given-names></string-name>, <string-name><surname>Tolaney</surname><given-names>SM</given-names></string-name>, <string-name><surname>Rugo</surname><given-names>HS</given-names></string-name>, <etal/></person-group>. <article-title>MONARCH 1, a phase II study of abemaciclib, a CDK4 and CDK6 inhibitor, as a single agent, in patients with refractory HR<sup>+</sup>/<italic>HER2</italic><sup>−</sup> metastatic breast cancer</article-title>. <source>Clin Cancer Res</source>. <year>2017</year>;<volume>23</volume>(<issue>17</issue>):<fpage>5218</fpage>-<lpage>5224</lpage>. doi:<pub-id pub-id-type="doi">10.1158/1078-0432.CCR-17-0754</pub-id><?supplied-pmid 28533223?><pub-id pub-id-type="pmid">28533223</pub-id></mixed-citation>
              </ref>
              <ref id="coi220102r24">
                <label>24</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Lindeman</surname><given-names>GJ</given-names></string-name>, <string-name><surname>Bowen</surname><given-names>R</given-names></string-name>, <string-name><surname>Jerzak</surname><given-names>KJ</given-names></string-name>, <etal/></person-group>. <article-title>Results from VERONICA: a randomized, phase II study of second-/third-line venetoclax (VEN) plus fulvestrant (F) versus F alone in estrogen receptor (ER)-positive, HER2-negative, locally advanced, or metastatic breast cancer (LA/MBC)</article-title>. <source>J Clin Oncol</source>. <year>2021</year>;<volume>39</volume>(<issue>15</issue>):<fpage>1</fpage>. doi:<pub-id pub-id-type="doi">10.1200/JCO.2021.39.15_suppl.1004</pub-id><pub-id pub-id-type="pmid">32986527</pub-id></mixed-citation>
              </ref>
              <ref id="coi220102r25">
                <label>25</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Rugo</surname><given-names>HS</given-names></string-name>, <string-name><surname>Lerebours</surname><given-names>F</given-names></string-name>, <string-name><surname>Ciruelos</surname><given-names>E</given-names></string-name>, <etal/></person-group>. <article-title>Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative study</article-title>. <source>Lancet Oncol</source>. <year>2021</year>;<volume>22</volume>(<issue>4</issue>):<fpage>489</fpage>-<lpage>498</lpage>. doi:<pub-id pub-id-type="doi">10.1016/S1470-2045(21)00034-6</pub-id><?supplied-pmid 33794206?><pub-id pub-id-type="pmid">33794206</pub-id></mixed-citation>
              </ref>
              <ref id="coi220102r26">
                <label>26</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Mosele</surname><given-names>F</given-names></string-name>, <string-name><surname>Stefanovska</surname><given-names>B</given-names></string-name>, <string-name><surname>Lusque</surname><given-names>A</given-names></string-name>, <etal/></person-group>. <article-title>Outcome and molecular landscape of patients with PIK3CA-mutated metastatic breast cancer</article-title>. <source>Ann Oncol</source>. <year>2020</year>;<volume>31</volume>(<issue>3</issue>):<fpage>377</fpage>-<lpage>386</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.annonc.2019.11.006</pub-id><?supplied-pmid 32067679?><pub-id pub-id-type="pmid">32067679</pub-id></mixed-citation>
              </ref>
              <ref id="coi220102r27">
                <label>27</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Rugo</surname><given-names>HS</given-names></string-name>, <string-name><surname>Bardia</surname><given-names>A</given-names></string-name>, <string-name><surname>Marmé</surname><given-names>F</given-names></string-name>, <etal/></person-group>. <article-title>Primary results from TROPiCS-02: a randomized phase 3 study of sacituzumab govitecan (SG) versus treatment of physician’s choice (TPC) in patients (pts) with hormone receptor–positive/<italic>HER2</italic>-negative (HR+/<italic>HER2</italic>−) advanced breast cancer</article-title>. <source>J Clin Oncol</source>. <year>2022</year>;<volume>40</volume>(<issue>17</issue>)(<supplement>suppl</supplement>):<fpage>LBA1001</fpage>-<lpage>LBA1001</lpage>. doi:<pub-id pub-id-type="doi">10.1200/JCO.2022.40.17_suppl.LBA1001</pub-id></mixed-citation>
              </ref>
              <ref id="coi220102r28">
                <label>28</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Modi</surname><given-names>S</given-names></string-name>, <string-name><surname>Jacot</surname><given-names>W</given-names></string-name>, <string-name><surname>Yamashita</surname><given-names>T</given-names></string-name>, <etal/>; <collab>DESTINY-Breast04 Trial Investigators</collab></person-group>. <article-title>Trastuzumab deruxtecan in previously treated <italic>HER2</italic>-low advanced breast cancer</article-title>. <source>N Engl J Med</source>. <year>2022</year>;<volume>387</volume>(<issue>1</issue>):<fpage>9</fpage>-<lpage>20</lpage>. doi:<pub-id pub-id-type="doi">10.1056/NEJMoa2203690</pub-id><?supplied-pmid 35665782?><pub-id pub-id-type="pmid">35665782</pub-id></mixed-citation>
              </ref>
              <ref id="coi220102r29">
                <label>29</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Kalinsky</surname><given-names>K</given-names></string-name>, <string-name><surname>Jacks</surname><given-names>LM</given-names></string-name>, <string-name><surname>Heguy</surname><given-names>A</given-names></string-name>, <etal/></person-group>. <article-title><italic>PIK3CA</italic> mutation associates with improved outcome in breast cancer</article-title>. <source>Clin Cancer Res</source>. <year>2009</year>;<volume>15</volume>(<issue>16</issue>):<fpage>5049</fpage>-<lpage>5059</lpage>. doi:<pub-id pub-id-type="doi">10.1158/1078-0432.CCR-09-0632</pub-id><?supplied-pmid 19671852?><pub-id pub-id-type="pmid">19671852</pub-id></mixed-citation>
              </ref>
              <ref id="coi220102r30">
                <label>30</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Xu</surname><given-names>J</given-names></string-name>, <string-name><surname>Wu</surname><given-names>X</given-names></string-name>, <string-name><surname>Zhou</surname><given-names>WH</given-names></string-name>, <etal/></person-group>. <article-title>Aurora-A identifies early recurrence and poor prognosis and promises a potential therapeutic target in triple negative breast cancer</article-title>. <source>PLoS One</source>. <year>2013</year>;<volume>8</volume>(<issue>2</issue>):<elocation-id>e56919</elocation-id>. doi:<pub-id pub-id-type="doi">10.1371/journal.pone.0056919</pub-id><?supplied-pmid 23437271?><pub-id pub-id-type="pmid">23437271</pub-id></mixed-citation>
              </ref>
            </ref-list>
            <notes notes-type="supplementary-material" id="note-COI220102-1">
              <supplementary-material id="note-COI220102-1-s" position="float" content-type="local-data">
                <label>Supplement 1.</label>
                <caption>
                  <p>Trial protocol</p>
                </caption>
                <media xlink:href="jamaoncol-e227949-s001.pdf">
                  <caption>
                    <p>Click here for additional data file.</p>
                  </caption>
                </media>
              </supplementary-material>
              <supplementary-material position="float" content-type="local-data">
                <label>Supplement 2.</label>
                <caption>
                  <p>eTable 1. Dose levels and modifications for alisertib</p>
                  <p>eTable 2. Safety stopping rule event summary and approved protocol changes</p>
                </caption>
                <media xlink:href="jamaoncol-e227949-s002.pdf">
                  <caption>
                    <p>Click here for additional data file.</p>
                  </caption>
                </media>
              </supplementary-material>
              <supplementary-material position="float" content-type="local-data">
                <label>Supplement 3.</label>
                <caption>
                  <p>Data sharing statement</p>
                </caption>
                <media xlink:href="jamaoncol-e227949-s003.pdf">
                  <caption>
                    <p>Click here for additional data file.</p>
                  </caption>
                </media>
              </supplementary-material>
            </notes>
          </back>
        </article>
      </metadata>
    </record>
  </GetRecord>
</OAI-PMH>
